Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Foreword

Foreword Am J Cancer 2004; 3 (1): 5-8 REVIEW ARTICLE 1175-6357/03/0001-0005/$25.00/0 & Adis Data Information BV 2004. All rights reserved. Jean-Louis Pujol Montpellier University Hospital, Montpellier, France It is a difficult exercise to describe the complex research out. The conclusion of most of the studies was that there were involved in developing two different cytotoxic drugs, gemcitabine differences in toxicity and compliance between gemcitabine– and pemetrexed, in an editorial. It is all the more difficult because cisplatin on the one hand and other combinations, based on a the writer of this editorial is involved in university- and hospital- platinum salt, on the other, but no increase in survival could be based research and so is more familiar with approaches for discerned. Many phase III studies have inaccurately concluded verifying concepts than with the strategies used for developing equivalence, when they were not designed to show such a result. therapeutic molecules. There are nonetheless places where the two This is the first type of ambiguity that is frequently seen in fields overlap, and where apposition of these studies can help the publications about phase III studies, in which a lack of difference search for an effective treatment for lung cancer to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Loading next page...
 
/lp/springer-journals/foreword-u4tyq9pt2f
Publisher
Springer Journals
Copyright
Copyright © 2004 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200403991-00002
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2004; 3 (1): 5-8 REVIEW ARTICLE 1175-6357/03/0001-0005/$25.00/0 & Adis Data Information BV 2004. All rights reserved. Jean-Louis Pujol Montpellier University Hospital, Montpellier, France It is a difficult exercise to describe the complex research out. The conclusion of most of the studies was that there were involved in developing two different cytotoxic drugs, gemcitabine differences in toxicity and compliance between gemcitabine– and pemetrexed, in an editorial. It is all the more difficult because cisplatin on the one hand and other combinations, based on a the writer of this editorial is involved in university- and hospital- platinum salt, on the other, but no increase in survival could be based research and so is more familiar with approaches for discerned. Many phase III studies have inaccurately concluded verifying concepts than with the strategies used for developing equivalence, when they were not designed to show such a result. therapeutic molecules. There are nonetheless places where the two This is the first type of ambiguity that is frequently seen in fields overlap, and where apposition of these studies can help the publications about phase III studies, in which a lack of difference search for an effective treatment for lung cancer to

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References